Hepatitis B Vaccine Trial (Phase I)
The enrollment of new participants for this study has already been completed (update as of November 6, 2025).
We kindly ask for your understanding and thank you for your interest!
If you are generally interested in participating in our clinical studies, we would be happy if you register without obligation.
Over three percent of the world's population (approx. 260 million people) are chronically infected with the hepatitis B virus (HBV). Worldwide, 880,000 people die every year as a result of HBV infection (including liver cirrhosis and liver cancer). Prophylactic vaccines are available to prevent HBV infection. There is currently no curative treatment for chronically infected people.
The Institute of Infectious Diseases and Tropical Medicine at the LMU University Hospital Munich is conducting a Phase I vaccine trial with the therapeutic vaccine candidate TherVacB against hepatitis B in collaboration with the Institute for Infection Research and Vaccine Development Hamburg (Prof. Addo) and Helmholtz Munich (Prof. Protzer). The study contributes to the research of a novel therapeutic approach to cure chronic hepatitis B in the TherVacB project.
TherVacB is a publicly funded academic research project. Further information on the project can be found at www.thervacb.eu and www.dzif.de.
We are looking for healthy women and men between the ages of 18 and 65 for the Phase I study.
The study includes a preliminary examination and 12 outpatient visits over a period of approx. 9 months.
General requirements for participation in the study
- 18-65 years
- in good health
for women: not pregnant or breastfeeding
not vaccinated against Mpox (formerly monkeypox) or hepatitis B
no hepatitis B infection in the past
- no regular intake of medication
- BMI (Body Mass Index): 18.5-32.0 kg/m²
- Body weight: at least 50 kg
In addition to comprehensive information about the study and in-depth medical care, you will receive an expense allowance of € 1,800.00 if you participate fully.
Contact for interested parties
Monday - Thursday:
9a.m. to 2.30 p.m.
Tel: 089 4400-59850
E-Mail:
impfstudien-tropeninstitut@
med.uni-muenchen.de
Please state the keyword "Hepatitis B" in your e-mail.
Cooperation partner
